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Abstract
Objective—Cardiomyopathy (CM) at delivery is increasing in prevalance. The objective of this
study was to determine what medical conditions are attributable to this increasing prevalance.
Design—Population prevalence study from 2000 to 2009.
Setting—The Nationwide Inpatient Sample (NIS).
Methods—Pregnant women admitted for delivery were identified in the NIS for the years
2000-2009 and temporal trends in pre-existing medical conditions and medical and obstetric
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complications at delivery admissions were determined by linear regression. The change in the
prevalence of CM among all pregnant women was compared to the change in the prevalance of
CM among pregnant women without pre-existing conditions or complications.
Main Outcome Measures—Prevalence of cardiomyopathy.
Results—The prevalence of CM increased from 0.25 per 1000 deliveries in 2000 to 0.43 per
1000 deliveries in 2009 (p<0.0001). Women with chronic hypertension had increased odds of
developing CM compared to women without chronic hypertension (odds ratio[OR] 13.2 [95% CI
12.5, 13.7]). The linear increase in chronic hypertension over the ten-year period was the single
identified pre-existing medical condition that explained the increasing prevalence of CM at
delivery (p=0.005 for the differences in the slopes for linear trend).
Conclusions—Pregnant women with chronic hypertenion are at an increased risk for CM at
delivery and the increasing prevalence of chronic hypertension is an important factor associated
with the increasing prevalence of CM at the time of delivery. Among women without chronic
hypertension, the prevalence of CM at delivery did not change during the time period.
Keywords
cardiomyopathy; hypertension; mortality; nationwide inpatient sample; pregnancy
INTRODUCTION
Pregnancy-associated cardiomyopathy, defined as either peripartum cardiomyopathy or
cardiomyopathy with primary causes during pregnancy, is relatively uncommon but is a
potentially life-threatening condition. As mortality from other pregnancy conditions, such as
hemorrhage and hypertensive disorders, has decreased in developing countries,
cardiomyopathy has accounted for an increasing proportion of maternal deaths. For
example, in the United States, the proportion of pregnancy-related deaths from
cardiomyopathy increased in the time period 1979-1986 to 1991-1997 and up to 11.5% in
the period 1998-2005, reaching almost 13% in 2005-2006.(1-5) The proportion of deaths
attributable to cardiomyopathy in pregnancy may be even higher in geographic locations
with a higher prevalence of this condition. A recent study reviewing preventable causes of
maternal death from 1995-1999 found that cardiomyopathy was the most common cause of
pregnancy-related death in North Carolina, representing 21% of all cases of maternal
mortality.(6) The increasing trends in the reported prevalence of cardiomyopathy
complicating pregnancy reported during the time period 1995-2006 are also concerning
given that cardiomyopathy is an important contributor to other severe medical complications
in pregnancy including cardiac arrest, acute myocardial infarction, pulmonary edema, and
acute respiratory distress syndrome.(7)
Pregnancy poses a number of challenges to the maternal cardiovascular system. Blood
volume increases by 50%, resulting in an increase in cardiac output by 30%-50% and
increased work of the heart.(8-10) Women with underlying heart disease may be at risk for
baseline cardiac dysfunction and their cardiac function may not tolerate the additional strain
caused by pregnancy. As cardiomyopathy complicating pregnancy has increased over the
time period 1995-2006,(7) the objective of this study was to identify pre-existing medical
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conditions and medical and obstetric complications that might explain the increasing
prevalence of cardiomyopathy at the time of delivery.
METHODS
The study was reviewed and declared exempt from review by the Duke University Medical
Center Institutional Review Board. We utilized the Nationwide Inpatient Sample (NIS) to
conduct a population prevalence study to determine what factors are associated with the
increasing prevalence of cardiomyopathy at the time of delivery. The NIS from the
Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality
(AHRQ) for years 2000 to 2009 was queried for all pregnancy-related discharges with a
diagnosis of cardiomyopathy. For the years in the study period, the NIS contains data from
7-8 million hospital admissions per year from approximately 1,000 hospitals in 28 (2000) to
44 (2009) states and is the largest all-payer inpatient care database in the United States. The
hospitals in the NIS are stratified based on ownership, bed size, teaching status, urban/rural
location, and region. Within each stratum, the NIS contains approximately 20% of U.S.
hospitals, representing a random sample. The NIS does not include data from rehabilitation
hospitals, long-term hospitals, psychiatric hospitals, and alcoholism or chemical dependency
treatment facilities, none of which are likely to have delivery admissions. Sampling
probabilities are proportional to the number of hospitals in each stratum. The sampling
frame comprises 90% of all US hospital discharges and the NIS provides sampling weights
that allow for calculation of national estimates. The information included in the NIS is
similar to that in a typical administrative discharge abstract with safeguards to protect the
privacy of individual patients, physicians, and hospitals. Although the nature of the data is
limited to discharge diagnoses and demographic information, the NIS allows for the study of
relatively rare conditions such as cardiomyopathy in women during pregnancy.
Using the NIS for each of the years 2000-2009, all records containing a pregnancy-related
discharge for delivery were identified. An admission for delivery was defined as any
discharge record that included an International Classification of Diseases, Clinical
Modification (ICD-9-CM) or Diagnosis-Related Group (DRG) delivery code. ICD-9-CM
delivery codes were 74 for cesarean section; 72, 73, and 75 for vaginal delivery; and V27
and 650 for general delivery codes. For the years 2000-2007, DRG codes 370 and 371 were
utilized to identify cesarean deliveries and codes 372, 373, 374, and 375 for vaginal
deliveries. For the years 2008 and 2009, DRG codes 765 and 766 were utilized to identify
cesarean deliveries and codes 767, 768, 774, and 775 for vaginal deliveries.(11-14)
Cardiomyopathy was defined by the ICD-9-CM codes 674.5, the code for peripartum
cardiomyopathy, and 425.x, the codes for cardiomyopathy secondary to primary causes.(15)
Although all etiologies of cardiomyopathy in pregnancy are not the same, in this study, we
elected to combine all types of cardiomyopathy. In a study utilizing a similar design, it was
reported that only a minority of cardiomyopathy diagnoses in pregnancy were consistent
with peripartum cardiomyopathy, while the majority represented cardiomyopathies
secondary to identifiable causes (primary cardiomyopathies).(15) For comorbidities, both
the ICD-9-CM code for a particular condition in pregnancy (i.e. 6xx code) and the general
ICD-9-CM code for that condition were used. (Table S1 for list of ICD-9-CM codes
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utilized) The number of deaths occurring during delivery admissions was determined for
each study year and were identified by having a discharge status as “DIED” in the NIS. The
sampling frame for events was limited to only delivery admissions. By focusing on delivery
admissions, since each woman only has one delivery per pregnancy, we were able to
estimate outcomes for individuals, rather than hospitalizations, as women could possibly
have more than one antepartum or postpartum hospitalization during a single pregnancy, but
not more than one hospitalization for delivery.
According to the currently accepted definition, peripartum cardiomyopathy may manifest
from the last month of pregnancy to 5 months after delivery. Although the majority of cases
of peripartum cardiomyopathy (about 50%) manifests in the first 6-8 weeks postpartum,
about one-third of cases are diagnosed during the delivery hospitalization. Thus, only
peripartum cardiomyopathies and other (primary) cardiomyopathies that were diagnosed
during delivery hospitalization are included in our study.
The analysis accounted for the weighted estimates of hospitalizations that were used by the
NIS. Two-way chi-square tests generated cell frequencies and P-values for demographics,
pre-existing medical conditions, and medical and obstetric complications among women
with and without cardiomyopathy. Logistic regression analyses were used to compute odds
ratios with 95% confidence intervals for age, race, pre-existing medical conditions, and
medical and obstetric complications among women with cardiomyopathy at delivery
compared to those women without cardiomyopathy. The rate of pre-existing medical
conditions and medical and obstetric complications among pregnant women with
cardiomyopathy at delivery were also calculated for each of the years from 2000 to 2009.
For each pre-existing medical condition and medical or obstetric complication, the rate of
the condition or outcome per 1000 deliveries was calculated for each of the 10 years. Linear
regression was then utilized to determine if the prevalence of each pre-existing medical
condition or incidence of each medical and obstetric complication varied significantly over
the 10-year time period. Next, to determine if any pre-existing medical conditions or
medical/obstetric complications affected the prevalence of cardiomyopathy at delivery, the
slope over the 10-year time period of the prevalence of cardiomyopathy for all subjects with
cardiomyopathy during a delivery admission was compared to the slope that was calculated
for subjects with cardiomyopathy who did not also have each of the listed pre-existing
medical conditions or medical/obstetric complications of interest, and the differences in the
two slopes was determined. A significant difference between the two slopes suggests that
the condition or complication affects the prevalence of cardiomyopathy. Finally, the
population attributable risk proportion for the contribution of chronic hypertension to the
development of cardiomyopathy was calculated.(16) Statistical significance for linear
regression was assigned as a P value < 0.01.(7) Statistical significance for all other analyses
was assigned as a P value < 0.05. All analyses were performed using SAS version 9.3 (SAS
Institute Inc, Cary, NC) and GraphPad Prism version 5.0 for Macintosh (GraphPad
Software, San Diego, CA).
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During the years 2000-2009, there were a weighted estimated 43,226,339 delivery
admissions within NIS. The overall age distribution for this time period was 34.8% ages
15-24, 27.0% ages 25-29, 23.4% ages 30-34, and 14.6% ages 35 and older. The age
distribution did not vary significantly over this time period except for a slight increase in the
proportion of women aged 25-29 from 26.5% in 2000 to 27.8% in 2009 (p<0.001 for age
25-29 and p>0.01 for all other age groups). The racial/ethnic distribution of women during a
delivery admission did not vary linearly over the time period, though 24.9% of the entries
over the 10-year time period had missing race/ethnicity data. The cesarean delivery rate over
the entire time period was 28.6% and increased linearly during the years 2000 to 2009
(p<0.001), from 22.2% in 2000 to 32.5% in 2009. Of the 3309 maternal deaths, 105 (3%)
occurred in women with a diagnosis of cardiomyopathy. The maternal mortality rate among
all women during a delivery admission did not change with time during the studied time
period (p=0.097).
The prevalence of cardiomyopathy at the time of a delivery admission increased during the
time period (p<0.001) from 0.25 per 1000 deliveries in 2000 to 0.43 per 1000 deliveries in
2009 (Figure 1A, Table S2). The change in the prevalence of other pre-existing medical and
obstetric conditions at delivery admissions was also calculated over the 10-year period.
There were significant linear increases (p<0.01) in the prevalence of congenital heart
disease, cardiac conduction disorders, history of ischemic heart disease, asthma, disorders of
pulmonary circulation, diabetes, thyroid disorders, systemic lupus erythematosus,
rheumatoid arthritis, thrombophilia/anti-phospholipid antibody syndrome,
thrombocytopenia, anemia, chronic hypertension, chronic renal failure, tobacco use, drug
use, gestational diabetes, preeclampsia, and fetal growth restriction during the 10-year study
period (Table S2, Figures 1B, 1C and S1). There were also significant linear decreases
(p<0.01) in the prevalence of valvular heart disease and fetal death during delivery
admissions during the ten-year time period (Table S2, Figure S1).
We also estimated trends in medical complications occurring during a delivery admission
over the 10-year period. There were significant linear increases (p<0.01) in the incidence of
acute respiratory distress syndrome, pulmonary embolism, sepsis, and acute renal failure
(Table S3, Figure S2). There were significant linear decreases (p<0.01) in the incidence of
pulmonary edema and postpartum bacterial infection (endometritis) during delivery
admissions during the 10-year time period (Table S3, Figure S2).
To determine if changes in the prevalence of pre-existing medical conditions or the
incidence of medical and obstetric complications were contributing to the increasing
prevalence of cardiomyopathy in pregnancy, we compared the slope calculated by linear
regression for the change in the prevalence of cardiomyopathy at delivery among all
pregnant women over the 10-year time period with the slope calculated by linear regression
for cardiomyopathy among subjects not having each of the medical or obstetric conditions/
complications of interest. When compared, a significant difference between the two slopes
suggested that the tested medical condition was associated, at least in part, with the change
in the prevalence of cardiomyopathy during the 10-year period. Of each of the tested pre-
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existing medical conditions or medical and obstetric complications, only chronic
hypertension affected the prevalence of cardiomyopathy in pregnancy (Table 1, Figure 2A,
Tables 2 and 3, Figures S3 and S4). For women without chronic hypertension, there was a
non-significant linear increase in the prevalence of cardiomyopathy (p=0.015) (Table 1,
Figure 2A). Furthermore, when the slope for the change in prevalence of cardiomyopathy
among all women was compared to the slope for the change in prevalence of cardiomypathy
among women without chronic hypertension, the slopes were significantly different
(p=0.005 for differences in slopes) demonstrating that chronic hypertension affected the
change in the prevalence of cardiomyopathy (Table 1, Figure 2A).
As women with chronic hypertension are at increased risk for developing preeclampsia, we
analyzed the data to determine the change in prevalence of women who had both chronic
hypertension and preeclampsia. There was a significant linear increase in the prevalence of
having both chronic hypertension and preeclampsia over the years 2000 to 2009 (p=0.0002,
R2=0.835, Figure 1D). Despite this increase in prevalence of having both chronic
hypertension and preeclampsia, women with both disorders did not account for the increased
prevalence of cardiomyopathy at delivery (p=0.804 for differences in the slopes of all
women with cardiomyopathy compared to women with cardiomyopathy who did not have
both chronic hypertension and preeclampsia (Table 1, Figure 2C).
When all women with cardiomyopathy were compared to women with cardiomyopathy who
did not have each of the other specified pre-existing medical conditions or medical and
obstetric complications, the difference in the linear trends was not significant. This suggests
that changes in the prevalence of these other pre-existing medical conditions or changes in
the incidence of the studied medical or obstetric complications did not affect the prevalence
of cardiomyopathy during admission for delivery (p>0.01 for the comparison of slopes,
Tables 2 and 3, Figures S3 and S4).
For women with chronic hypertension, the crude relative risk of developing cardiomyopathy
at delivery was 13.2 (95% CI 12.5, 13.7) compared to women without chronic hypertension.
Based on these estimates, the population attributable risk proportion of cardiomyopathy (the
fraction of cases of cardiomyopathy that could theoretically be prevented by eliminating
chronic hypertension as a risk factor) was 14.9%. Among all women with chronic




Based on hospital discharge data, the prevalence of cardiomyopathy at the time of admission
for delivery increased during the 10 years from 2000 to 2009. Of the pre-existing medical
conditions and medical and obstetric complications tested, the change in prevalence of
chronic hypertension among pregnant women was associated with the increasing prevalence
of cardiomyopathy at the time of an admission for delivery. Though we acknowledge that
this work does not prove that chronic hypertension causes cardiomyopathy, women with
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chronic hypertension did have increased odds for cardiomyopathy compared to women
without chronic hypertension.
Interpretation
Cardiomyopathy in pregnancy is classified as either peripartum cardiomyopathy or
cardiomyopathy secondary to an identifiable (primary) cause.(17) Although the majority of
cardiomyopathies associated with pregnancy are cardiomyopathies secondary to identifiable
primary causes, Whitehead et al demonstrated that among cardiomyopathy-associated
pregnancy-related deaths, peripartum cardiomyopathy was a more common diagnosis.(15,
18) Regardless, many risk factors for peripartum cardiomyopathy and cardiomyopathy
secondary to identifiable primary causes do overlap. The etiology of peripartum
cardiomyopathy is unknown but the classically taught risk factors of multiparity, advanced
maternal age, multiple gestation, preeclampsia, and African American race were first
reported by Demakis in 1971 in a case series of 27 women. These investigators coined the
term peripartum cardiomyopathy and developed diagnostic criteria for the disease.(19) Since
then, other case series of women with peripartum cardiomyopathy have found that advanced
maternal age, multiparty, hypertension, preeclampsia, use of tocolytic agents (prolonged
beta-adrenergic agonist therapy), and multiple gestation continue to be common among
women with peripartum cardiomyopathy.(20-25) Conversely, cardiomyopathies secondary
to identifiable causes may have more clear risk factors and etiologies. There are numerous
etiologies for cardiomyopathies including viral and other infectious disease, myocarditis,
ischemic heart disease, hypertension, substance abuse, connective tissue disorders, and
infiltrative disorders.(26) As our study does not demonstrate causation, it is unknown how
screening and treatment of chronic hypertension among reproductive-age women would
affect the prevalence of cardiomyopathy in pregnancy, but chronic hypertension is a
potentially modifiable risk factor.
Strengths and Limitations
Using the NIS, we were able to search for associated medical conditions that may be
associated with cardiomyopathy presenting in pregnancy, but there are limitations to using
these data. The NIS relies on accurate medical coding at discharge. We were unable to
determine if changes in other known risk factors for cardiomyopathy-particularly obesity,
multiparity, and the use of specific drugs were associated with the increased prevalence.(20,
23, 27) Next, there are wide ranges in reported sensitivity and specificity for medical and
obstetric conditions and procedures in large databases that rely on ICD-9 codes.(28-30) Low
sensitivity for coding chronic conditions among obstetric patients has been reported.(28)
Because of potential low sensitivity for chronic conditions, our reported estimates may be
low and may be more representative of those with more severe conditions. Furthermore, it is
possible that some medical comorbidities were not coded for subjects during a delivery
admission, especially if that condition was not an active aspect of the woman’s admission
for delivery. For example, according to the most recently available data, about 5% of
reproductive age women in the US reported taking antihypertensive medications while only
about 2% of delivery hospital discharge records had an ICD-9-CM code for chronic
hypertension.(31-33) Regardless, from our dataset, we were able to demonstrate that chronic
hypertension significantly affected the increasing prevalence of cardiomyopathy during
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pregnancy. It is unknown if milder cases of cardiomyopathy were identified and if not,
whether chronic hypertension also is associated with the change in prevalence of these
milder forms. Race and ethnicity did not affect the change in prevalence of cardiomyopathy
in our study but approximately 25% of NIS entries have race/ethnicity data as not coded.
Thus it is unknown if race and ethnicity would play a stronger role in the increasing
prevalence of cardiomyopathy if race and ethnicity were better coded in the NIS.
Due to limitations of large databases that rely on identification of subjects using ICD-9
diagnosis codes, we elected to define pregnancy-associated cardiomyopathy as all forms of
cardiomyopathy in pregnancy (peripartum cardiomyopathy and cardiomyopathy due to
secondary causes). Kuklina et al found that 80% of subjects with the specific peripartum
cardiomyopathy ICD-9 code, also had codes for heart disease or chronic conditions that are
associated with dilated forms of cardiomyopathy.(15) Because of this lack of specificity in
the ICD-9 codes, it is not possible using the NIS or other large databases, to make
conclusions about peripartum cardiomyopathy versus cardiomyopathy due to secondary
causes. Our conclusions are, therefore, not specific for peripartum cardiomyopathy, but are
general to all forms of cardiomyopathy that are present at delivery. Lastly, our data do not
establish causality. We identified an association of chronic hypertension with
cardiomyopathy at delivery, but it is impossible to know if chronic hypertension causes
cardiomyopathy. Regardless, large databases such as the NIS are useful at identifying such
associations, especially for rare conditions. Further research utilizing detailed clinical data is
needed to expand on the association of chronic hypertension with cardiomyopathy.
Conclusion
In summary, women with chronic hypertension are at increased risk for developing
cardiomyopathy during pregnancy, and cardiomyopathy in pregnancy is increasing in
prevalence at the time of delivery. The increased prevalence of cardiomyopathy in
pregnancy is at least in part due to the increasing prevalence of chronic hypertension among
women who become pregnant. Further work is required to identify specific factors among
women with pre-existing heart disease or chronic hypertension, which may further increase
their risk for cardiomyopathy.
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Figure 1. Trends in the prevalence of cardiomyopathy, chronic hypertension, preeclampsia, and
chronic hypertension with preeclampsia at delivery admissions, the 2000 – 2009 Nationwide
Inpatient Sample (n = 43,226,239)
Error bars demonstrate 95% confidence intervals. A. There was an increase in the linear
trend for cardiomyopathy diagnosed at delivery admissions during the 10-year study period
(p<0.001, R2=0.90), increasing from 0.25 cases per 1000 deliveries in 2000 to 0.43 per 1000
deliveries in 2009. B and C. There was an increase in the linear trend for chronic
hypertension (B. p<0.001, R2=0.99) and preeclampsia (C. p<0.001, R2=0.90), increasing
from 10.1 per 1000 deliveries in 2000 to 19.6 per 1000 deliveries in 2009, and from 62.5 per
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1000 deliveries in 2000 to 74.0 per 1000 deliveries in 2009, respectively. D. There was an
increase in the linear trend for chronic hypertension with preeclampsia (D. p<0.001,
R2=0.84), increasing from 1.8 per 1000 deliveries in 2000 to 4.7 per 1000 deliveries in 2009.
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Figure 2. Trends in the prevalence of cardiomyopathy in women without hypertensive disorders
of pregnancy compared to all women with cardiomyopathy at delivery admissions, the 2000 –
2009 Nationwide Inpatient Sample (n=43,226,239)
Error bars demonstrate 95% confidence intervals. To determine if pre-existing medical
conditions or medical and obstetric complications occurring during a delivery admission
were accounting for the increased prevalence of cardiomyopathy over the study period, the
linear trend for cardiomyopathy among women who also did not have each of the
preexisting medical conditions or medical and obstetrics complications listed (Tables 2 and
3) were compared to the linear trend for all women with cardiomyopathy. A. The difference
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in the slopes for the linear trends of all women with cardiomyopathy compared to women
with cardiomyopathy who did not have chronic hypertension were significantly different
(p=0.005), suggesting that chronic hypertension was contributing to the increasing
prevalence of cardiomyopathy during the study time period. B. and C. In contrast, there
were no differences in the slope for linear trend among all women with cardiomyopathy
compared to women with cardiomyopathy who did not have preeclampsia (B) or compared
to women with cardiomyopathy who did not have both chronic hypertension and
preeclampsia (C). (Abbreviations: CM=cardiomyopathy, HTN=hypertension,
Prex=preeclampsia)
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Table 1
Comparison of linear trends of CM among all women at a delivery admission to women with CM who did not
have chronic hypertension, preeclampsia, or chronic hypertension with preeclampsia during the years 2000 –
2009 by linear regression (significance defined as P-value < 0.01). See Figure 2 for graphical representation.






All women with Cardiomyopathy (CM) 0.021 0.90 <0.001 --
CM among those women without
chronic hypertension 0.009 0.55 0.015 0.005
CM among those women without
preeclampsia 0.015 0.80 <0.001 0.120
CM among those women without
chronic hypertension and preeclampsia 0.020 0.88 <0.001 0.804
a
Slope (Δy/Δx) reported is the change in the listed condition per 1000 deliveries (Δy) per year (Δx) (Figure 2)
b
Comparison of the slope obtained from the linear regression of the trends for CM among all women to the slope obtained from linear regression
for women with CM who did not also have chronic hypertension, preeclampsia, or chronic hypertension with preeclampsia.
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Table 2
Comparison of linear trends of CM among all women at a delivery admission to women with CM who did not
also have the listed pre-existing medical condition during the years 2000 – 2009 by linear regression
(significance defined as P-value < 0.01). See Figure S3 for graphical representation.






Cardiomyopathy (CM) 0.021 0.90 <0.001 --
CM without Congenital heart disease 0.021 0.89 <0.001 0.97
CM without Valvular heart disease 0.021 0.93 <0.001 0.91
CM without Conduction disorders 0.019 0.90 <0.001 0.52
CM without History of ischemic heart dz. 0.021 0.89 <0.001 0.97
CM without Asthma 0.020 0.86 <0.001 0.76
CM without Disorders of pulmonary circ. 0.200 0.87 <0.001 0.92
CM without Diabetes 0.019 0.85 <0.001 0.60
CM without Thyroid disorders 0.021 0.90 <0.001 0.95
CM without SLE 0.021 0.89 <0.001 0.93
CM without Rheumatoid arthritis 0.021 0.89 <0.001 0.89
CM without Thrombophilia 0.021 0.88 <0.001 0.98
CM without Thrombocytopenia 0.021 0.89 <0.001 0.99
CM without Anemia 0.017 0.85 <0.001 0.27
CM without Tobacco use 0.019 0.87 <0.001 0.72
CM without Drug use 0.020 0.90 <0.001 0.96
CM without Alcohol use 0.021 0.89 <0.001 0.88
CM without Chronic renal failure 0.020 0.87 <0.001 0.92
CM without Preeclampsia 0.015 0.80 <0.001 0.120
CM without Gestational diabetes 0.021 0.85 <0.001 0.92
CM without Multiple gestation 0.020 0.87 <0.001 0.83
CM without Fetal growth restriction 0.021 0.87 <0.001 0.96
CM without Placental abruption 0.021 0.89 <0.001 0.99
CM without Fetal death 0.021 0.89 <0.001 0.94
a
Slope (Δy/Δx) reported is the change in the listed condition per 1000 deliveries (Δy) per year (Δx) (Figure 2 and Figure S3)
b
Comparison of the slope obtained from the linear regression of the trends for CM among all women to the slope obtained from linear regression
for women with CM who did not also have each of the listed variables (women with CM who do not have the condition listed).
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Table 3
Comparison of linear trends in CM among all women at a delivery admission to women with CM who did not
have the listed medical event during the years 2000 – 2009 by linear regression (significance defined as P-
value < 0.01). See Figure S4 for graphical representation.






Cardiomyopathy (CM) 0.021 0.90 <0.001 --
CM without Myocardial infarction 0.021 0.89 <0.001 0.95
CM without Ventricular fibrillation 0.021 0.89 <0.001 0.94
CM without Cardiac arrest 0.021 0.89 <0.001 0.99
CM without Acute heart failure 0.015 0.92 <0.001 0.053
CM without Pneumonia 0.020 0.89 <0.001 0.83
CM without RDS 0.020 0.87 <0.001 0.84
CM without Pulmonary edema 0.021 0.89 <0.001 0.95
CM without Stoke/CVA 0.021 0.89 <0.001 0.84
CM without Pulmonary embolism 0.021 0.89 <0.001 0.95
CM without DVT 0.021 0.89 <0.001 0.91
CM without Sepsis 0.021 0.88 <0.001 0.98
CM without Influenza 0.021 0.89 <0.001 0.90
CM without Postpartum bacterial infection 0.021 0.90 <0.001 0.76
CM without Acute renal failure 0.020 0.87 <0.001 0.80
a
Slope (Δy/Δx) reported is the change in the listed condition per 1000 deliveries (Δy) per year (Δx) (Figure S4)
b
Comparison of the slope obtained from the linear regression of the trends in CM among all women to the slope obtained from linear regression for
each of the listed variables (women with CM who do not have the condition listed).
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